Acutaas Chemicals projects a 25% revenue increase for fiscal year 2027. The company aims to generate ₹1,000 crore specifically from its contract development and manufacturing organization (CDMO) services.
Commercial production of battery electrolyte additives at the Jhagadia facility will drive this growth. Successful client validation of the CDMO pipeline molecules further supports the outlook.
The firm focuses on high-purity battery chemicals and semiconductor materials to leverage India's production-linked incentive (PLI) schemes. This strategy also aims to benefit from the global China+1 supply chain shift.
Risks include revenue concentration in specific oncology drug contracts and potential facility commissioning delays. Despite strong Q1 revenue growth, the stock recently declined following conservative full-year guidance.